Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.00.8128PMID 16260701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684

  2023cited by this paper
• Adjuvante Therapie des Melanoms

  2006cited by this paper
• Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

  2004cited by this paper
• Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

  2004cited by this paper
• Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.

  2004cited by this paper
• Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: pharmacological activity and mechanisms of action.

  2004cited by this paper
• The natural history of melanoma and factors predicting outcome

  2003cited by this paper
• An update on adjuvant interferon for melanoma.

  2002cited by this paper
• European approach to the treatment of malignant melanoma.

  2002cited by this paper
• Zur Sterblichkeit am kutanen invasiven malignen Melanom Übersicht unter besonderer Berücksichtigung der Geschlechterverteilung

  2001cited by this paper
• [Mortality of invasive malignant cutaneous melanoma. A review with special consideration of gender distribution].

  2001cited by this paper
• High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

  2001cited by this paper
• Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study

  2001cited by this paper
• A new American Joint Committee on Cancer staging system for cutaneous melanoma

  2000cited by this paper
• High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

  2000cited by this paper
• Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

  2000cited by this paper
• Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21.

  1999cited by this paper
• [Current comments on the dermatological oncology working groups' work on high dose therapy with interferon alpha 2b].

  1999cited by this paper
• A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.

  1999cited by this paper
• Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

  1998cited by this paper
• Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases

  1998cited by this paper
• Fatality and interferon alpha for malignant melanoma.

  1998cited by this paper
• Fatality and interferon α for malignant melanoma

  1998cited by this paper
• Adjuvante Interferon-α-Therapie beim Melanom Stellungnahme der Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

  1998cited by this paper
• Combined effects of interferon-α2a and 13-cisretinoic acid on human melanoma cell growth and STAT protein expression

  1998cited by this paper
• Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma.

  1998cited by this paper
• [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].

  1998cited by this paper
• Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

  1998cited by this paper
• Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma.

  1997cited by this paper
• Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

  1996cited by this paper
• Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma.

  1996cited by this paper
• Retinoids and interferons in non-melanoma skin cancer.

  1996cited by this paper
• Combination of highly purified human leukocyte interferon α and 13-cis-retinoic acid for the treatment of metastiatic melanoma

  1995cited by this paper
• [Retinoids in chemoprevention of tumors of the skin and mucous membranes. Theoretical principles and practical applications].

  1994cited by this paper
• Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study.

  1994cited by this paper
• Retinoide in der Chemoprävention von Haut- und Schleimhauttumoren

  1994cited by this paper
• Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma.

  1994cited by this paper
• Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines.

  1994cited by this paper
• Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma

  1993cited by this paper
• Inhibition of K1735-M2 melanoma cell invasion in vitro by retinoic acid

  1993cited by this paper
• Long-Term Therapy With Low-Dose Isotretinoin for Prevention of Basal Cell Carcinoma: A Multicenter Clinical Trial

  1992cited by this paper
• 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin.

  1992cited by this paper
• Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group.

  1992cited by this paper
• Differential susceptibility of cultured human melanoma cell lines to enhancement by retinoic acid of intercellular adhesion molecule 1 expression.

  1992cited by this paper
• 13-cis-Retinoic Acid and Interferon α -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin

  1992cited by this paper
• 13-cis-Retinoic Acid Plus Interferon α -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

  1992cited by this paper
• Retinoids in cancer therapy.

  1992cited by this paper
• 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.

  1992cited by this paper
• Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines.

  1991cited by this paper
• Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype.

  1990cited by this paper
• Treatment of advanced malignant melanoma with interferon alpha and etretinate.

  1988cited by this paper
• Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin.

  1988cited by this paper
• Treatment of advanced squamous cell carcinoma of the skin with isotretinoin.

  1987cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper

• Retinoids in cancer chemoprevention and therapy: Meta-analysis of randomized controlled trials

  2022influential citation
• Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review.

  2020cites this paper
• Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer

  2019cites this paper
• Dermatological indications for the use of isotretinoin beyond acne

  2018cites this paper
• Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

  2017cites this paper
• (Neo)adjuvant systemic therapy for melanoma.

  2017cites this paper
• Open Access book

  2017cites this paper
• Retinoic acid receptors: from molecular mechanisms to cancer therapy.

  2015cites this paper
• LRAT Overexpression Diminishes Intracellular Levels of Biologically Active Retinoids and Reduces Retinoid Antitumor Efficacy in the Murine Melanoma B16F10 Cell Line

  2015cites this paper
• Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.

  2015cites this paper
• Regression of B‐RAF inhibitor associated keratoacanthomas by acitretin – how do retinoids act on the RAF/MEK/ERK‐signaling pathway?

  2014cites this paper
• Knockdown of lecithin retinol acyltransferase increases all‐trans retinoic acid levels and restores retinoid sensitivity in malignant melanoma cells

  2014cites this paper
• Adjuvant Treatment of Melanoma

  2013cites this paper
• Adjuvant Treatment of Melanoma

  2013cites this paper
• Cell Cycle and Senescence Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identi fi es a Link Between p 14 ARF and RAR b Signaling

  2013cites this paper
• Interferon alpha for the adjuvant treatment of cutaneous melanoma.

  2013cites this paper
• Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RARβ Signaling

  2013cites this paper
• The influence of sex hormones on melanoma

  2012cites this paper
• Interferon: Current Status and Future Prospects in Cancer Therapy

  2011cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Melanoma During Pregnancy

  2011cites this paper
• Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

  2010cites this paper
• Utility of adjuvant systemic therapy in melanoma

  2009cites this paper
• Diagnosis and treatment of melanoma brain metastasis: a literature review.

  2009cites this paper
• Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.

  2008cites this paper
• Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

  2007cites this paper
• A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors

  2006cites this paper
• American Society of Clinical Oncology 41st Annual Meeting

  2005cites this paper
• Building upon the standard of care in adjuvant therapy of high-risk melanoma.

  2005cites this paper